

Abstract of the Disclosure

The present invention is directed to a pharmaceutical composition containing  
5 a cancer-treating effective amount of a class of prostacyclin derivatives, and a  
pharmaceutically acceptable carrier, and to kits and methods of employing the same  
for the treatment of cancer.

2025 RELEASE UNDER E.O. 14176